Literature DB >> 22179358

Targeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?

Vasileios C Kyttaris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22179358      PMCID： PMC3243898          DOI： 10.1097/CCM.0b013e318232d2b6

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  12 in total

Review 1.  Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies.

Authors:  Hans von Baeyer
Journal:  Ther Apher       Date:  2002-08

2.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 3.  Clinical practice. Thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

4.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Authors:  Antoine Froissart; Marc Buffet; Agnès Veyradier; Pascale Poullin; François Provôt; Sandrine Malot; Michael Schwarzinger; Lionel Galicier; Philippe Vanhille; Jean-Paul Vernant; Dominique Bordessoule; Bertrand Guidet; Elie Azoulay; Eric Mariotte; Eric Rondeau; Jean-Paul Mira; Alain Wynckel; Karine Clabault; Gabriel Choukroun; Claire Presne; Jacques Pourrat; Mohamed Hamidou; Paul Coppo
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

5.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

Authors:  Marie Scully; Hannah Cohen; Jamie Cavenagh; Sylvia Benjamin; Richard Starke; Sally Killick; Ian Mackie; Samuel J Machin
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

7.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

8.  Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Authors:  Bertrand Godeau; Raphael Porcher; Olivier Fain; François Lefrère; Pierre Fenaux; Stéphane Cheze; Anne Vekhoff; Marie-Paule Chauveheid; Jerôme Stirnemann; Lionel Galicier; Emmanuelle Bourgeois; Stéphanie Haiat; Bruno Varet; Michel Leporrier; Thomas Papo; Mehdi Khellaf; Marc Michel; Philippe Bierling
Journal:  Blood       Date:  2008-05-07       Impact factor: 22.113

9.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Authors:  Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster
Journal:  Arthritis Rheum       Date:  2003-08

10.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.